Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN ORIE HERZBERG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1861873275
CMS profile
1359383
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$106.30

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $106.30 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
AtriCure, Inc. $55.53 1
Novartis Pharmaceuticals Corporation $50.77 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN ORIE HERZBERG

NPI 1861873275 · CMS profile ID 1359383

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861873275?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861873275?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861873275?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1861873275?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $106.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $50.7711/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893744511 CMS
AtriCure, Inc. $55.5310/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932219505 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $106.30 2
PY2023 $970.06 4
PY2024 $4,751.70 5
PY2025 $18,408.32 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,023,233.04 218
PY2024 Principal investigator $909,794.38 160
PY2023 Principal investigator $870,048.69 649
PY2022 Principal investigator $8,640.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

218 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $5,882.00 12/18/2025 Non-covered Recipient Entity
Trustees of Columbia University in the City of New York
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211674386
Principal investigator 1 Genentech, Inc. $29,882.00 12/15/2025 Non-covered Recipient Entity
Trustees of Columbia University in the City of New York
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211674378
Principal investigator 1 Genentech, Inc. $1,620.00 12/15/2025 Non-covered Recipient Entity
Trustees of Columbia University in the City of New York
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211674389
Principal investigator 1 Astellas Pharma Inc $3,984.27 12/11/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365645
Principal investigator 1 Astellas Pharma Inc $3,984.27 12/11/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365647
Principal investigator 1 Astellas Pharma Inc $3,565.35 12/11/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365649
Principal investigator 1 Astellas Pharma Inc $415.13 12/11/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365651
Principal investigator 1 Astellas Pharma Inc $415.13 12/11/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365653
Principal investigator 1 Astellas Pharma Inc $415.13 12/11/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365655
Principal investigator 1 Genentech, Inc. $2,789.00 11/18/2025 Non-covered Recipient Entity
Trustees of Columbia University in the City of New York
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211674372
Principal investigator 1 Astellas Pharma Inc $543.57 10/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365641
Principal investigator 1 Astellas Pharma Inc $415.13 10/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365643
Principal investigator 1 Genentech, Inc. $20,800.00 08/22/2025 Non-covered Recipient Entity
Trustees of Columbia University in the City of New York
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211674368
Principal investigator 1 Eli Lilly and Company $955.88 07/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NY
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187891062
Principal investigator 1 Astellas Pharma Inc $3,902.85 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365607
Principal investigator 1 Astellas Pharma Inc $4,706.52 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365609
Principal investigator 1 Astellas Pharma Inc $5,492.22 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365611
Principal investigator 1 Astellas Pharma Inc $4,706.52 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365613
Principal investigator 1 Astellas Pharma Inc $4,153.02 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365615
Principal investigator 1 Astellas Pharma Inc $4,706.52 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365617
Principal investigator 1 Astellas Pharma Inc $3,902.85 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365619
Principal investigator 1 Astellas Pharma Inc $4,153.02 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365621
Principal investigator 1 Astellas Pharma Inc $3,902.85 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365623
Principal investigator 1 Astellas Pharma Inc $2,394.00 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365625
Principal investigator 1 Astellas Pharma Inc $4,153.02 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365627
Principal investigator 1 Astellas Pharma Inc $3,902.85 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365629
Principal investigator 1 Astellas Pharma Inc $4,706.52 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365631
Principal investigator 1 Astellas Pharma Inc $4,153.02 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365633
Principal investigator 1 Astellas Pharma Inc $3,902.85 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365635
Principal investigator 1 Astellas Pharma Inc $4,706.52 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365637
Principal investigator 1 Astellas Pharma Inc $4,153.02 06/06/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365639
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365427
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365429
Principal investigator 1 Astellas Pharma Inc $5,253.16 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365431
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365433
Principal investigator 1 Astellas Pharma Inc $1,972.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365435
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365437
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365439
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365441
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365443
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365445
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365447
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365449
Principal investigator 1 Astellas Pharma Inc $1,359.45 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365451
Principal investigator 1 Astellas Pharma Inc $1,972.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365453
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365455
Principal investigator 1 Astellas Pharma Inc $5,154.72 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365457
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365459
Principal investigator 1 Astellas Pharma Inc $3,454.65 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365461
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365463
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365465
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365467
Principal investigator 1 Astellas Pharma Inc $3,638.48 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365469
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365471
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365473
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365475
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365477
Principal investigator 1 Astellas Pharma Inc $1,972.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365479
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365481
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365483
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365485
Principal investigator 1 Astellas Pharma Inc $1,359.45 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365487
Principal investigator 1 Astellas Pharma Inc $3,414.57 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365489
Principal investigator 1 Astellas Pharma Inc $3,414.57 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365491
Principal investigator 1 Astellas Pharma Inc $5,154.72 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365493
Principal investigator 1 Astellas Pharma Inc $2,647.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365495
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365497
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365499
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365501
Principal investigator 1 Astellas Pharma Inc $5,253.16 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365503
Principal investigator 1 Astellas Pharma Inc $2,647.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365505
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365507
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365509
Principal investigator 1 Astellas Pharma Inc $5,253.16 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365511
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365513
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365515
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365517
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365519
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365521
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365523
Principal investigator 1 Astellas Pharma Inc $4,369.02 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365525
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365527
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365529
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365531
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365533
Principal investigator 1 Astellas Pharma Inc $3,638.48 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365535
Principal investigator 1 Astellas Pharma Inc $3,414.57 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365537
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365539
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365541
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365543
Principal investigator 1 Astellas Pharma Inc $3,454.65 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365545
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365547
Principal investigator 1 Astellas Pharma Inc $4,369.02 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365549
Principal investigator 1 Astellas Pharma Inc $5,154.72 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365551
Principal investigator 1 Astellas Pharma Inc $1,972.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365553
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365555
Principal investigator 1 Astellas Pharma Inc $2,647.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365557
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365559
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365561
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365563
Principal investigator 1 Astellas Pharma Inc $3,815.52 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365565
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365567
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365569
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365571
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365573
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365575
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365577
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365579
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365581
Principal investigator 1 Astellas Pharma Inc $5,154.72 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365583
Principal investigator 1 Astellas Pharma Inc $5,253.16 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365585
Principal investigator 1 Astellas Pharma Inc $3,638.48 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365587
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365589
Principal investigator 1 Astellas Pharma Inc $3,638.48 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365591
Principal investigator 1 Astellas Pharma Inc $4,369.02 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365593
Principal investigator 1 Astellas Pharma Inc $4,369.02 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365595
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365597
Principal investigator 1 Astellas Pharma Inc $2,647.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365599
Principal investigator 1 Astellas Pharma Inc $3,638.48 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365601
Principal investigator 1 Astellas Pharma Inc $3,565.35 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365603
Principal investigator 1 Astellas Pharma Inc $3,984.27 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365605
Principal investigator 1 Astellas Pharma Inc $2,394.00 04/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365383
Principal investigator 1 Astellas Pharma Inc $3,565.35 04/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365385
Principal investigator 1 Astellas Pharma Inc $3,525.27 04/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365387
Principal investigator 1 Astellas Pharma Inc $4,369.02 04/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365391
Principal investigator 1 Eli Lilly and Company $90,433.57 04/24/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NY
A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS No dispute reported 06/30/2026 1187891060
Principal investigator 1 Genentech, Inc. $38,505.00 04/18/2025 Non-covered Recipient Entity
Trustees of Columbia University in the City of New York
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211674342
Principal investigator 1 Astellas Pharma Inc $2,242.00 04/16/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365379
Principal investigator 1 Astellas Pharma Inc $2,242.00 04/16/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365381
Principal investigator 1 Astellas Pharma Inc $3,815.52 04/16/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365389
Principal investigator 1 Astellas Pharma Inc $3,565.35 04/16/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365393
Principal investigator 1 Astellas Pharma Inc $2,394.00 04/16/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365395
Principal investigator 1 Astellas Pharma Inc $4,369.02 04/16/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365397
Principal investigator 1 Astellas Pharma Inc $405.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365399
Principal investigator 1 Astellas Pharma Inc $10,800.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365401
Principal investigator 1 Astellas Pharma Inc $12,150.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365403
Principal investigator 1 Astellas Pharma Inc $4,320.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365405
Principal investigator 1 Astellas Pharma Inc $1,500.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365407
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365409
Principal investigator 1 Astellas Pharma Inc $1,620.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365411
Principal investigator 1 Astellas Pharma Inc $2,025.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365413
Principal investigator 1 Astellas Pharma Inc $1,215.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365415
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365417
Principal investigator 1 Astellas Pharma Inc $1,215.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365419
Principal investigator 1 Astellas Pharma Inc $1,080.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365421
Principal investigator 1 Astellas Pharma Inc $2,835.00 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365423
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/25/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365425
Principal investigator 1 AstraZeneca Pharmaceuticals LP $54,940.95 03/24/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185540555
Principal investigator 1 Daiichi Sankyo Inc. $30,240.00 02/03/2025 Non-covered Recipient Entity
Trustees Of Columbia University In The City Of New York
DS7300-189 No dispute reported 06/30/2026 1223385965
Principal investigator 1 Daiichi Sankyo Inc. $1,114.00 02/03/2025 Non-covered Recipient Entity
Trustees Of Columbia University In The City Of New York
DS7300-189 No dispute reported 06/30/2026 1223385967
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 02/03/2025 Non-covered Recipient Entity
Trustees Of Columbia University In The City Of New York
DS7300-189 No dispute reported 06/30/2026 1223385969
Principal investigator 1 Daiichi Sankyo Inc. $486.00 02/03/2025 Non-covered Recipient Entity
Trustees Of Columbia University In The City Of New York
DS7300-189 No dispute reported 06/30/2026 1223385971
Principal investigator 1 Amgen Inc. $50,542.35 01/30/2025 Non-covered Recipient Entity
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246640455
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365275
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365279
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365281
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365283
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365285
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365287
Principal investigator 1 Astellas Pharma Inc $5,253.16 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365289
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365291
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365293
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365295
Principal investigator 1 Astellas Pharma Inc $415.13 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365297
Principal investigator 1 Astellas Pharma Inc $415.13 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365299
Principal investigator 1 Astellas Pharma Inc $1,480.95 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365301
Principal investigator 1 Astellas Pharma Inc $1,972.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365303
Principal investigator 1 Astellas Pharma Inc $5,253.16 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365305
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365307
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365309
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365311
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365313
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365315
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365317
Principal investigator 1 Astellas Pharma Inc $3,414.57 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365319
Principal investigator 1 Astellas Pharma Inc $2,394.00 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365321
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365323
Principal investigator 1 Astellas Pharma Inc $5,253.16 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365325
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365327
Principal investigator 1 Astellas Pharma Inc $2,242.00 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365329
Principal investigator 1 Astellas Pharma Inc $1,972.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365331
Principal investigator 1 Astellas Pharma Inc $5,253.16 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365333
Principal investigator 1 Astellas Pharma Inc $5,253.16 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365335
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365337
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365341
Principal investigator 1 Astellas Pharma Inc $5,253.16 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365343
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365345
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365349
Principal investigator 1 Astellas Pharma Inc $3,815.52 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365351
Principal investigator 1 Astellas Pharma Inc $5,154.72 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365359
Principal investigator 1 Astellas Pharma Inc $1,731.12 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365361
Principal investigator 1 Astellas Pharma Inc $415.13 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365363
Principal investigator 1 Astellas Pharma Inc $1,972.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365365
Principal investigator 1 Astellas Pharma Inc $3,565.35 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365367
Principal investigator 1 Astellas Pharma Inc $3,454.65 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365369
Principal investigator 1 Astellas Pharma Inc $4,369.02 01/30/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365371
Principal investigator 1 Astellas Pharma Inc $16,036.46 01/15/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365251
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365249
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365253
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365255
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365257
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365259
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365261
Principal investigator 1 Astellas Pharma Inc $1,071.90 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365263
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365265
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365267
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365269
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365271
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365273
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365277
Principal investigator 1 Astellas Pharma Inc $168.65 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365339
Principal investigator 1 Astellas Pharma Inc $170.10 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365347
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365353
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365355
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365357
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365373
Principal investigator 1 Astellas Pharma Inc $168.75 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365375
Principal investigator 1 Astellas Pharma Inc $168.85 01/02/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365377